Theralase Releases Financial Results for First Quarter 2013
30 Mai 2013 - 10:10PM
Access Wire
Toronto, Ontario - May 30, 2013, Theralase Technologies Inc.
(TSXV: TLT) released its first quarter 2013 financial results
today, demonstrating an increase in profitability by 27% year over
year, while successfully advancing its patented therapeutic laser
and cancer destruction technologies .
Total revenue for the three months ended March 31, 2013
decreased to $342,900 from $448,359 for the same period in 2012, a
24% decrease.
Selling expenses decreased by 42%, to $109,391 from $188,390 for
the same period in 2012. The percentage decrease was due to reduced
spending on salaries on sales personnel and a reduction in
marketing costs.
Administrative expenses decreased by 19% to $249,767 from
$309,213 for the same period in 2012. The decrease in
administrative expenditures is due to reductions in administrative
personnel compensation, stock based compensation and rent.
Research and development costs decreased to $199,597 from
$249,158 for the same period in 2012. This represents a 20%
decrease in expenditures, due to the approaching completion of
research and development costs of the patented TLC-2000 therapeutic
laser technology.
The net loss for three month period ended March 31, 2013 was
$332,435, which included $56,829 of net non-cash expenses compared
to a net loss in 2012 of $453,285, which included $84,313 of net
non-cash expenses, demonstrating an improvement of 27% year over
year.
The net loss is a reflection of the ongoing commitment of
Theralase to invest in the next level of therapeutic laser and
cancer destruction technologies, from existing therapeutic laser
sales.
"Theralase is preparing for the launch of its next generation
patented TLC-2000 biofeedback therapeutic laser technology in
4Q2013 that will revolutionize the therapeutic laser industry,"
stated Roger Dumoulin-White, President and CEO of Theralase. "In
addition our cancer technology has evolved past the proof of
concept stage and is now being readied for investigation in the
destruction of bladder cancer in humans in 2014.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, manufactures and markets
patented, superpulsed laser technology used in healing injured
tissue and destroying cancer. Theralase technology is safe and
effective in eliminating pain, reducing inflammation and
accelerating tissue regeneration of numerous nerve, muscle and
joint injuries. Theralase is actively developing patented
technology that is able to target and destroy cancers, bacteria and
viruses when light activated.
The complete interim consolidated financial statements and
MD&A for three month period ending March 31, 2013 may be viewed
at www.theralase.com and www.sedar.com.
This press release contains forward-looking statements, which
reflect the Company's current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein.
The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchanges) accepts responsibility for the adequacy or
accuracy of this release.
For More Information, please contact:
Roger Dumoulin - White,
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260
amandel@theralase.com
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Theralase Technologies (TSXV:TLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024